Abstract |
During 2012, a number of respiratory drug projects and individual agents were discontinued, for a variety of reasons, including toxicity, lack of efficacy, commercial re-evaluation and change in corporate focus. These included three antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2), which had been evaluated in allergic respiratory disease and (in one case) chronic obstructive pulmonary disease ( COPD), and other agents intended for the treatment of asthma, COPD, pulmonary hypertension and lung fibrosis. These have been reviewed against the background of a general reduction in respiratory research by the pharmaceutical industry.
|
Authors | Noel J C Snell |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 23
Issue 3
Pg. 411-5
(Mar 2014)
ISSN: 1744-7658 [Electronic] England |
PMID | 24490845
(Publication Type: Journal Article, Review)
|
Chemical References |
- Drugs, Investigational
- Respiratory System Agents
|
Topics |
- Animals
- Drug Industry
- Drugs, Investigational
(pharmacology, therapeutic use)
- Humans
- Lung Diseases
(drug therapy)
- Respiratory System Agents
(pharmacology, therapeutic use)
- Treatment Outcome
|